Cisplatin Cancer Research Results

Cisplatin, Cisplatin: Click to Expand ⟱

Features:

Cisplatin is a chemotherapy medication used to treat various types of cancer. It is a platinum-based drug that works by interfering with the DNA of cancer cells, preventing them from reproducing and ultimately leading to cell death.
Cisplatin (cis-diamminedichloroplatinum II; CDDP) is a platinum-based chemotherapeutic agent that forms covalent DNA crosslinks, primarily intrastrand adducts at adjacent guanine bases. These distort DNA structure, block replication and transcription, and activate DNA damage response pathways (ATM/ATR → p53), leading to cell-cycle arrest and apoptosis. Secondary mechanisms include ROS generation, stress MAPK activation, and modulation of NF-κB. Clinical resistance frequently involves enhanced DNA repair (ERCC1/NER), altered drug transport (CTR1, ATP7A/B), and increased antioxidant defenses. Major toxicities include nephrotoxicity, ototoxicity, and peripheral neuropathy.

Rank	Pathway / Axis	Cancer / Tumor Context	Normal Tissue Context	TSF	Primary Effect	Notes / Interpretation
1	DNA crosslink formation (intrastrand adducts)	DNA adducts ↑; replication block ↑	Normal dividing cells also affected	P, R, G	Direct DNA cytotoxicity	Cisplatin forms covalent intrastrand crosslinks (primarily at adjacent guanines), distorting DNA and blocking replication and transcription.
2	DNA damage response (ATM / ATR → p53)	Checkpoint activation ↑; p53 signaling ↑	↔ (toxicity in proliferating tissues)	R, G	Damage signaling cascade	DNA distortion activates ATM/ATR pathways leading to p53-mediated cell-cycle arrest and apoptosis.
3	Intrinsic apoptosis (mitochondrial pathway)	Bax ↑; Bcl-2 ↓; caspase-9/3 ↑	Nephrotoxicity & ototoxicity risk	G	Execution of cell death	Persistent DNA damage triggers mitochondrial outer membrane permeabilization and caspase activation.
4	Cell-cycle arrest (G2/M emphasis)	G2/M arrest ↑	↔	G	Cytostasis → apoptosis	Cells accumulate in G2/M phase due to unrepaired DNA lesions.
5	ROS generation / oxidative stress	ROS ↑ (secondary mechanism)	Oxidative injury ↑ (kidney, cochlea)	R, G	Stress amplification	Cisplatin increases mitochondrial ROS and oxidative stress, contributing to cytotoxicity and organ toxicity.
6	MAPK signaling (JNK / p38 activation)	Stress MAPK activation ↑	↔	R, G	Stress-response signaling	JNK and p38 activation contribute to apoptosis and stress signaling.
7	NF-κB activation (resistance axis)	NF-κB ↑ may promote survival	↔	R, G	Resistance modulation	NF-κB activation can reduce sensitivity; inhibition enhances cytotoxicity in some models.
8	DNA repair pathways (NER / ERCC1)	NER ↑ → resistance	—	G	Resistance determinant	Nucleotide excision repair (ERCC1) removes platinum adducts; high ERCC1 correlates with resistance.
9	Drug transport (CTR1 uptake; ATP7A/B efflux)	CTR1 ↓ or ATP7A/B ↑ → resistance	—	G	Exposure constraint	Copper transporters influence intracellular cisplatin accumulation and resistance.
10	Clinical toxicity profile	—	Nephrotoxicity, ototoxicity, neurotoxicity	—	Translation constraint	Major dose-limiting toxicities arise from DNA damage and oxidative stress in normal tissues.

Time-Scale Flag (TSF): P / R / G

P: 0–30 min (DNA aquation and initial adduct formation)
R: 30 min–3 hr (checkpoint activation / stress signaling)
G: >3 hr (apoptosis, phenotype outcomes, resistance development)

Scientific Papers found: Click to Expand⟱

1339-

2DG,

Cisplatin,

2-Deoxy-d-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells

in-vitro,

HNSCC,

FaDu

"highlight2" >ChemoSen↑, "highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >other↓,

1295-

AG,

Cisplatin,

Chemosensitizing Effect of Astragalus Polysaccharides on Nasopharyngeal Carcinoma Cells by Inducing Apoptosis and Modulating Expression of Bax/Bcl-2 Ratio and Caspases

in-vivo,

Laryn,

mice

"highlight2" >AntiTum↑, "highlight2" >Apoptosis↑, "highlight2" >Bcl-2↓, "highlight2" >BAX↑, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >Bax:Bcl2↑,

322-

AgNPs,

Cisplatin,

Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin

in-vitro,

Ovarian,

A2780S

 25nm AgNPs capped with polyvinylpyrrolidone (PVP

 15ug/mL

 IC50: 7.9ug/mL : 3.1uM for combination treatment

in-vitro,

Ovarian,

SKOV3

in-vitro,

Ovarian,

OVCAR-3

 745ug/mL

 less sensitive to AgNPs

"highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >GSH/GSSG↓,

257-

AL,

Cisplatin,

Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors

in-vitro,

NSCLC,

A549

 10μg/ml (LD) and 40μg/ml (HD) allicin for 24hr

 ~30µg/ml

"highlight2" >ROS↑, "highlight2" >HIF-1↓, "highlight2" >E-cadherin↑, "highlight2" >N-cadherin↓, "highlight2" >antiOx↓, "highlight2" >Dose↝,

299-

ALA,

Cisplatin,

PacT,

Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line

in-vitro,

Ovarian,

OVCAR-3

"highlight2" >MMP9↓, "highlight2" >MMP11↓, "highlight2" >MAPK↓,

1235-

ALA,

Cisplatin,

α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway

in-vitro,

Nor,

HEI-OC1

20μM cisplatin, 0-2mM(ALA)

ex-vivo,

NA,

"highlight2" >ROS↑, "highlight2" >HO-1↓, "highlight2" >*toxicity↓, "highlight2" >chemoP↑, "highlight2" >*ROS↓, "highlight2" >*HO-1↑, "highlight2" >*SOD1↑, "highlight2" >*NRF2↑,

1350-

And,

Cisplatin,

Synergistic antitumor effect of Andrographolide and cisplatin through ROS-mediated ER stress and STAT3 inhibition in colon cancer

in-vitro,

Colon,

"highlight2" >ChemoSen↑, "highlight2" >ER Stress↑, "highlight2" >STAT3↓, "highlight2" >ROS↑,

6397-

ANE,

Cisplatin,

Synergistic Effect of Anethole and Platinum Drug Cisplatin against Oral Cancer Cell Growth and Migration by Inhibiting MAPKase, Beta-Catenin, and NF-κB Pathways

in-vitro,

SCC,

Ca9-22

"highlight2" >AntiCan↑, "highlight2" >ChemoSen↑, "highlight2" >TumCP↓, "highlight2" >MMP↓, "highlight2" >ROS↑, "highlight2" >MAPK↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >NF-kB↓, "highlight2" >EMT↓, "highlight2" >Casp↑,

581-

Api,

Cisplatin,

The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy

in-vitro,

Pca,

CD44+

15uM / 7.5uM for 48

CD44+PCa

"highlight2" >Bcl-2↓, "highlight2" >survivin↓, "highlight2" >Casp8↑, "highlight2" >P53↑, "highlight2" >Sharpin↓, "highlight2" >APAF1↑, "highlight2" >p‑Akt↓, "highlight2" >NF-kB↓, "highlight2" >P21↑, "highlight2" >Cyc↓, "highlight2" >CDK2↓, "highlight2" >CDK4/6↓, "highlight2" >Snail↓, "highlight2" >ChemoSen↑,

583-

Api,

Cisplatin,

Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study

in-vitro,

Laryn,

HEp2

40uM - 160 uM

"highlight2" >PI3K/Akt↓, "highlight2" >GLUT1↓, "highlight2" >Akt↓,

584-

Api,

Cisplatin,

Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms

in-vivo,

Var,

Eighty Swiss albino male mice

"highlight2" >Beclin-1↑, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >JNK↑, "highlight2" >Mcl-1↓, "highlight2" >Ki-67↓,

578-

Api,

Cisplatin,

Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis

in-vitro,

Lung,

A549

30 uM

Multiple tumor cell types

in-vitro,

BC,

MCF7

apigenin at 30 µM with cisplatin at 2.5, 5.0, and 10.0 µM

in-vitro,

CRC,

HCT116

in-vitro,

Pca,

HeLa

in-vitro,

Lung,

H1299

"highlight2" >p‑P53↑,

564-

ART/DHA,

Cisplatin,

Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling

in-vitro,

NA,

HN30

"highlight2" >JAK2↓, "highlight2" >STAT3↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >Mcl-1↓, "highlight2" >Bcl-xL↓, "highlight2" >cycD1/CCND1↓, "highlight2" >VEGF↓, "highlight2" >TumCCA↑, "highlight2" >ChemoSen↑,

1368-

Ash,

Cisplatin,

Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’

in-vitro,

Colon,

HT-29

1 μg/mL, 5 μg/mL and 10 μg/mL W. somnifera for 48 h

in-vitro,

BC,

MDA-MB-231

"highlight2" >tumCV↓, "highlight2" >*toxicity↓, "highlight2" >ROS↑, "highlight2" >mitResp↓, "highlight2" >ChemoSen↑,

5426-

ASTX,

Cisplatin,

Astaxanthin Prevents a Decrease of Hemopoietic Activity in Head and Neck Cancer Patients Receiving Cisplatin Chemotherapy (Randomized Controlled Trial)

Trial,

HNSCC,

astaxanthin 2x4 mg

"highlight2" >ROS↓, "highlight2" >SOD↑, "highlight2" >MDA↓, "highlight2" >eff↑,

2628-

Ba,

Cisplatin,

Baicalein alleviates cisplatin-induced acute kidney injury by inhibiting ALOX12-dependent ferroptosis

in-vitro,

Nor,

HK-2

"highlight2" >*RenoP↑, "highlight2" >*12LOX↓, "highlight2" >*Ferroptosis↓,

2627-

Ba,

Cisplatin,

Baicalein, a Bioflavonoid, Prevents Cisplatin-Induced Acute Kidney Injury by Up-Regulating Antioxidant Defenses and Down-Regulating the MAPKs and NF-κB Pathways

"highlight2" >RenoP↑, "highlight2" >*iNOS↑, "highlight2" >*TNF-α↓, "highlight2" >*IL6↓, "highlight2" >*NF-kB↓, "highlight2" >*MAPK↓, "highlight2" >*ERK↓, "highlight2" >*JNK↓, "highlight2" >*antiOx↑, "highlight2" >*NRF2↓, "highlight2" >*HO-1↑, "highlight2" >*Cyt‑c∅, "highlight2" >*Casp3∅, "highlight2" >*Casp9∅, "highlight2" >*PARP∅,

2622-

Ba,

Cisplatin,

Rad,

Natural Baicalein-Rich Fraction as Radiosensitizer in Combination with Bismuth Oxide Nanoparticles and Cisplatin for Clinical Radiotherapy

in-vitro,

BC,

MDA-MB-231

in-vitro,

BC,

MCF7

"highlight2" >RadioS↑,

5181-

BBR,

Cisplatin,

Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer

in-vitro,

GC,

SGC-7901

in-vitro,

GC,

BGC-823

"highlight2" >tumCV↓, "highlight2" >MDR1↓, "highlight2" >ChemoSen↑, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >mTOR↓,

6497-

BCP,

Cisplatin,

Beta-Caryophyllene Enhances the Anti-Tumor Activity of Cisplatin in Lung Cancer Cell Lines through Regulating Cell Cycle and Apoptosis Signaling Molecules

in-vitro,

Lung,

"highlight2" >TumCG↓, "highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >toxicity↓, "highlight2" >ChemoSen↑, "highlight2" >P21↑, "highlight2" >Bcl-xL↑, "highlight2" >Bcl-2↓, "highlight2" >EMT↓, "highlight2" >E-cadherin↑, "highlight2" >eff↑, "highlight2" >MMP↓,

5651-

BNL,

Cisplatin,

Natural borneol sensitizes human glioma cells to cisplatin-induced apoptosis by triggering ROS-mediated oxidative damage and regulation of MAPKs and PI3K/AKT pathway

in-vitro,

GBM,

U251

in-vitro,

GBM,

U87MG

"highlight2" >ChemoSen↑, "highlight2" >tumCV↓, "highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >ATR↑, "highlight2" >ATM↑, "highlight2" >P53↑, "highlight2" >Histones↑, "highlight2" >eff↓, "highlight2" >Casp3↑, "highlight2" >Casp7↑, "highlight2" >Casp9↑,

730-

Bor,

Cisplatin,

The Effect of Boric Acid and Borax on Oxidative Stress, Inflammation, ER Stress and Apoptosis in Cisplatin Toxication and Nephrotoxicity Developing as a Result of Toxication

in-vivo,

NA,

rats

"highlight2" >*ROS↓, "highlight2" >*Inflam↓, "highlight2" >RenoP↑,

1450-

Bos,

Cisplatin,

3-Acetyl-11-keto-β-boswellic acid (AKBA) induced antiproliferative effect by suppressing Notch signaling pathway and synergistic interaction with cisplatin against prostate cancer cells

in-vitro,

Pca,

DU145

16.50 µM at 48 h

"highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >Casp↑, "highlight2" >Apoptosis↑, "highlight2" >Bax:Bcl2↑, "highlight2" >TumCCA?, "highlight2" >cycD1/CCND1↓, "highlight2" >CDK4↓, "highlight2" >P21↑, "highlight2" >p27/CDKN1B↑, "highlight2" >NOTCH↓, "highlight2" >ChemoSen↑,

5862-

carbop,

Cisplatin,

Molecular Mechanisms of Resistance and Toxicity Associated with Platinating Agents

Review,

Var,

"highlight2" >DNAdam↑, "highlight2" >ER Stress↑, "highlight2" >UPR↑, "highlight2" >ATF4↑, "highlight2" >ATF6↑, "highlight2" >XBP-1↑, "highlight2" >GRP78/BiP↑, "highlight2" >NP/CIPN↝, "highlight2" >toxicity↝, "highlight2" >eff↑, "highlight2" >TrxR1⇅,

5919-

Cats,

Cisplatin,

Uncaria tomentosa Leaves Decoction Modulates Differently ROS Production in Cancer and Normal Cells, and Effects Cisplatin Cytotoxicity

in-vitro,

Liver,

HepG2

580 µg/mL

"highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >Apoptosis↑, "highlight2" >Casp3↑, "highlight2" >Casp7↑, "highlight2" >NF-kB↓, "highlight2" >selectivity↑, "highlight2" >ChemoSen↑, "highlight2" >chemoP↑,

5965-

CEL,

Cisplatin,

Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway

in-vitro,

OS,

MG63

"highlight2" >COX2/PTGS2↓, "highlight2" >ChemoSen↑, "highlight2" >MDR1↓, "highlight2" >MRP1/ABCC1↓, "highlight2" >E-cadherin↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >Apoptosis↑, "highlight2" >TumCCA↑, "highlight2" >TumCG↓, "highlight2" >P-gp/ABCB1↓, "highlight2" >PI3K↓, "highlight2" >Akt↓,

6138-

CHr,

Cisplatin,

Chrysin protects against cisplatin-induced colon. toxicity via amelioration of oxidative stress and apoptosis: Probable role of p38MAPK and p53

in-vivo,

Nor,

Wistar rats once daily for 14 consecutive days at the doses of 25 and 50 mg/kg body weight orally in corn oil.

"highlight2" >*toxicity↝, "highlight2" >eff↑, "highlight2" >chemoP↑, "highlight2" >*ROS↓, "highlight2" >*MAPK↑, "highlight2" >*P53↑, "highlight2" >GSH↓,

444-

CUR,

Cisplatin,

LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells

vitro+vivo,

CRC,

HCT8

10 μM, 48 h; 1 g/kg/week, 42 days

"highlight2" >TumVol↓, "highlight2" >Apoptosis↑, "highlight2" >Bcl-2↓, "highlight2" >Cyt‑c↑, "highlight2" >BAX↑, "highlight2" >cl‑Casp3↑, "highlight2" >cl‑PARP1↑, "highlight2" >miR-497↑, "highlight2" >KCNQ1OT1↓,

1411-

CUR,

Cisplatin,

Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects

Review,

Var,

"highlight2" >ChemoSen↑, "highlight2" >*ROS↓, "highlight2" >*NF-kB↓, "highlight2" >TumCCA↑,

6678-

DCA,

Cisplatin,

Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma

Trial,

HNSCC,

double-blind phase II study added DCA to cisplatin-based CRT in patients with LA-HNSCC.

"highlight2" >PDK1 / PDPK1↓, "highlight2" >OS∅, "highlight2" >lactateProd↓, "highlight2" >toxicity↝, "highlight2" >FAO↑,

6734-

Dipy,

Cisplatin,

Adenosine enhances cisplatin sensitivity in human ovarian cancer cells

in-vitro,

Ovarian,

"highlight2" >eff↑, "highlight2" >eff↓, "highlight2" >ADO↓,

6353-

DRE,

Cisplatin,

Insights Into Protective Mechanisms of Dandelion Leaf Extract Against Cisplatin-Induced Nephrotoxicity in Rats: Role of Inhibitory Effect on Inflammatory and Apoptotic Pathways

in-vivo,

Nor,

DLE control received 500 mg/kg daily

Thirty-two male Wistar rats were divided into 4 groups:

"highlight2" >*antiOx↑, "highlight2" >*Inflam↓, "highlight2" >*Apoptosis↓, "highlight2" >*NF-kB↓, "highlight2" >*Cyt‑c↓, "highlight2" >*DNAdam↓, "highlight2" >*GSH↑, "highlight2" >*SOD↑, "highlight2" >*Albumin↝, "highlight2" >*creat↓, "highlight2" >*BUN↓, "highlight2" >*RenoP↑, "highlight2" >*lipid-P↓, "highlight2" >*TNF-α↓, "highlight2" >*Casp3↓, "highlight2" >*Casp9↓, "highlight2" >*chemoP↑,

6621-

Ech,

Cisplatin,

Experimental Evaluation of Protective Activity of Echinacea pallida against Cisplatin Toxicity

in-vivo,

Nor,

mice

"highlight2" >chemoP↑, "highlight2" >RenoP↑,

6333-

Eug,

Cisplatin,

Rad,

Eugenol Exerts Apoptotic Effect and Modulates the Sensitivity of HeLa Cells to Cisplatin and Radiation

in-vitro,

Cerv,

HeLa

"highlight2" >TumCP↓, "highlight2" >LDH↝, "highlight2" >ChemoSen↑, "highlight2" >RadioS↑, "highlight2" >Casp3↑, "highlight2" >BAX↑, "highlight2" >Cyt‑c↑, "highlight2" >Casp9↑, "highlight2" >Bcl-2↓, "highlight2" >COX2/PTGS2↓, "highlight2" >IL1β↓, "highlight2" >ROS↑, "highlight2" >NF-kB↓, "highlight2" >COX2/PTGS2↓, "highlight2" >TumCCA↓, "highlight2" >Thiols↓, "highlight2" >GSH↓,

949-

FIS,

ATAGJ,

Cisplatin,

Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1α Signaling Pathway

in-vivo,

BC,

Walker256

10,20,30g/day

in-vitro,

BC,

Walker256

10,20,30uM and 5uM(Cis)

indicating that the cisplatin group could substantially inhibit the migration of Walker 256 cells in both low and high dose fisetin groups

"highlight2" >Akt↓, "highlight2" >Hif1a↓, "highlight2" >p‑Akt↓,

7032-

GA,

Cisplatin,

Gallic acid: a polyphenolic compound potentiates the therapeutic efficacy of cisplatin in human breast cancer cells

in-vitro,

BC,

MCF7

in-vitro,

Nor,

MCF10

"highlight2" >ChemoSen↑, "highlight2" >tumCV↓, "highlight2" >Apoptosis↑, "highlight2" >selectivity↑, "highlight2" >*ROS↓, "highlight2" >eff↑, "highlight2" >*chemoP↑, "highlight2" >Dose↝,

7031-

GA,

Cisplatin,

Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non‑small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway

in-vitro,

Lung,

A549

"highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >BAX↑, "highlight2" >Bcl-2↓, "highlight2" >ChemoSen↑, "highlight2" >JAK↓, "highlight2" >STAT3↓,

1966-

GamB,

Cisplatin,

Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling

in-vitro,

Lung,

A549

in-vitro,

Lung,

NCIH1299

"highlight2" >TumCCA↑, "highlight2" >PARP↑, "highlight2" >eff↑, "highlight2" >ROS↑, "highlight2" >ChemoSen↑,

801-

GAR,

Cisplatin,

Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers

in-vivo,

HNSCC,

0.5 mg/kg

mouse

"highlight2" >Apoptosis↑, "highlight2" >cycD1/CCND1↓, "highlight2" >Bcl-2↓, "highlight2" >survivin↓, "highlight2" >VEGF↓, "highlight2" >TumCG↓, "highlight2" >Ki-67↓, "highlight2" >CD31/PECAM-1↓,

805-

GAR,

Cisplatin,

PacT,

Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells

Review,

NA,

"highlight2" >ERK↓, "highlight2" >PI3K/Akt↓, "highlight2" >Wnt/(β-catenin)↓, "highlight2" >STAT3↓, "highlight2" >NF-kB↓, "highlight2" >ChemoSen↑, "highlight2" >COX2/PTGS2↓, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >BAX↑, "highlight2" >Bcl-2↓, "highlight2" >VEGF↓, "highlight2" >TGF-β↓, "highlight2" >HATs↓, "highlight2" >E-cadherin↑, "highlight2" >Vim↓, "highlight2" >Zeb1↓, "highlight2" >ZEB2↓, "highlight2" >Let-7↑, "highlight2" >MMP9↓, "highlight2" >TumCCA↑, "highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >IL6↓, "highlight2" >NOTCH1↓, "highlight2" >antiNeop↑,

828-

GAR,

Cisplatin,

Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells

in-vitro,

Ovarian,

OVCAR-3

"highlight2" >tumCV↓, "highlight2" >cl‑PARP↑, "highlight2" >cl‑Casp3↑, "highlight2" >BAX↑, "highlight2" >p‑PI3K↓, "highlight2" >p‑Akt↓, "highlight2" >NF-kB↓,

7215-

GBE,

Cisplatin,

Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer

vitro+vivo,

NSCLC,

xenograft nude mouse

"highlight2" >AntiCan↑, "highlight2" >TumAuto↑, "highlight2" >ChemoSen↑, "highlight2" >Iron↑, "highlight2" >lipid-P↑, "highlight2" >Ferroptosis↑, "highlight2" >xCT/SLC7A11↓, "highlight2" >GPx4↓, "highlight2" >GSH/GSSG↓, "highlight2" >ROS↑, "highlight2" >NRF2↓, "highlight2" >HO-1↓, "highlight2" >MMP↓,

7144-

GI,

Cisplatin,

A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin

Trial,

Var,

 121 patients received ginger and 123 placebo

"highlight2" >Dose↝, "highlight2" >Nausea∅, "highlight2" >Vomit∅,

7242-

Gink,

Cisplatin,

Ginkgetin reverses cisplatin resistance in cervical cancer by regulating the Nrf2/HO-1 signaling pathway to induce ferroptosis

in-vitro,

Cerv,

HeLa

"highlight2" >TumCP↓, "highlight2" >NRF2↓, "highlight2" >ROS↑, "highlight2" >i-Iron↑, "highlight2" >GSH↓, "highlight2" >SOD↓, "highlight2" >Catalase↓, "highlight2" >lipid-P↑, "highlight2" >ACSL4↑, "highlight2" >NO↓, "highlight2" >GPx4↓, "highlight2" >Ferroptosis↑,

7483-

H2,

Cisplatin,

Molecular hydrogen attenuates cisplatin-induced nephrotoxicity by modulating β-hydroxybutyrate metabolism

in-vivo,

Nor,

HK-2

cisplatin-induced AKI mouse model

"highlight2" >RenoP↑, "highlight2" >BHB↑, "highlight2" >HMGCS2↑, "highlight2" >chemoP↑, "highlight2" >*IL2↓, "highlight2" >*IL6↓, "highlight2" >*MCP1/CCL2↓, "highlight2" >*TNF-α↓, "highlight2" >*KeyT↝, "highlight2" >*Inflam↓, "highlight2" >*ROS↓, "highlight2" >*MMP↑, "highlight2" >*ATP↑, "highlight2" >*MFN2↑, "highlight2" >*PGC-1α↑, "highlight2" >*BUN↓, "highlight2" >*creat↓,

7878-

isoO,

Cisplatin,

Isoorientin Attenuates Cisplatin-Induced Nephrotoxicity Through the Inhibition of Oxidative Stress and Apoptosis via Activating the SIRT1/SIRT6/Nrf-2 Pathway

in-vivo,

Nor,

mice

"highlight2" >*antiOx↑, "highlight2" >*RenoP↑, "highlight2" >*chemoP↑, "highlight2" >*SIRT1↑, "highlight2" >*SIRT6↑, "highlight2" >*NRF2↑, "highlight2" >*HO-1↑, "highlight2" >*NQO1↑, "highlight2" >*NOX4↓, "highlight2" >*ROS↓, "highlight2" >*MPO↓, "highlight2" >*MDA↓, "highlight2" >*SOD↑, "highlight2" >*GSH↑,

7871-

isoO,

Cisplatin,

Isoorientin reverses lung cancer drug resistance by promoting ferroptosis via the SIRT6/Nrf2/GPX4 signaling pathway

vitro+vivo,

Lung,

"highlight2" >ChemoSen↑, "highlight2" >i-Iron↑, "highlight2" >i-MDA↑, "highlight2" >*i-ROS↑, "highlight2" >GSH↓, "highlight2" >Ferroptosis↑, "highlight2" >NRF2↓, "highlight2" >GPx4↓, "highlight2" >SIRT6↓,

8051-

IVM,

Cisplatin,

rMETase,

Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal Fibroblasts

in-vitro,

Lung,

A549

"highlight2" >Dose↝, "highlight2" >ChemoSen↑, "highlight2" >selectivity↑,

8067-

KAE,

Cisplatin,

Kaempferol Induces Cell Death and Sensitizes Human Head and Neck Squamous Cell Carcinoma Cell Lines to Cisplatin

in-vitro,

HNSCC,

"highlight2" >AntiCan↑, "highlight2" >OCR↓, "highlight2" >i-ATP↓, "highlight2" >TumCMig↓, "highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >ChemoSen↑,

1064-

LT,

Cisplatin,

Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells

vitro+vivo,

Lung,

LNM35

25-200μM

intraperitoneal injection (20mg/kg/day for 18days)

in-vitro,

CRC,

HT-29

in-vitro,

Liver,

HepG2

in-vitro,

BC,

MCF7

in-vitro,

BC,

MDA-MB-231

"highlight2" >Casp3↑, "highlight2" >Casp7↑, "highlight2" >HDAC↓,

Showing Research Papers: 1 to 50 of 67
Page 1 of 2 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 67

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3, Ferroptosis↓, 1, GSH↑, 2, HO-1↑, 3, lipid-P↓, 1, MDA↓, 1, MFN2↑, 1, MPO↓, 1, NOX4↓, 1, NQO1↑, 1, NRF2↓, 1, NRF2↑, 2, ROS↓, 7, i-ROS↑, 1, SOD↑, 2, SOD1↑, 1,

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1, MMP↑, 1, PGC-1α↑, 1,

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1, BUN↓, 2, KeyT↝, 1, SIRT1↑, 1,

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1, Casp3↓, 1, Casp3∅, 1, Casp9↓, 1, Casp9∅, 1, Cyt‑c↓, 1, Cyt‑c∅, 1, Ferroptosis↓, 1, iNOS↑, 1, JNK↓, 1, MAPK↓, 1, MAPK↑, 1,

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1, P53↑, 1, PARP∅, 1, SIRT6↑, 1,

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL2↓, 1, IL6↓, 2, Inflam↓, 3, MCP1/CCL2↓, 1, NF-kB↓, 3, TNF-α↓, 3,

Clinical Biomarkers(tgid=22) ⓘ

Albumin↝, 1, creat↓, 2, IL6↓, 2,

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 3, RenoP↑, 3, toxicity↓, 2, toxicity↝, 1,
Total Targets: 53

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:197  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Cisplatin Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Transcription & Epigenetics(tgid=7) ⓘ

Protein Folding & ER Stress(tgid=8) ⓘ

Autophagy & Lysosomes(tgid=9) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Barriers & Transport(tgid=15) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Home Page